Clinical Trials
-
AI-designed vaccine passes first human trial, targets multiple coronaviruses
/ HTML. So we can have headings and paragraphs . Must not add new info. Must keep facts: AI-designed vaccine from University…
-
Takeda’s Oveporexton Meets All Endpoints in Two Phase 3 Narcolepsy Type 1 Trials
In July 2025, Takeda announced that its experimental wake‑promoting drug, oveporexton, successfully completed phase 3 clinical testing for narcolepsy. The trial results…
-
Mazdutide Meets All Key Goals in Chinese Phase III Obesity Trial, Innovent Says
China, May 21, 2025 — infopulsetoday.com — New clinical data released in May 2025 show that the investigational drug mazdutide, a once-weekly…
-
FDA Approves Vertex’s Journavx, the First New Class of Pain Medicine in Over 20 Years
Vertex Pharmaceuticals is awaiting a regulatory decision on suzetrigine, a non-opioid analgesic designed for moderate to severe acute pain. The drug, which…
-
Pfizer Drug Ponsegromab Boosts Weight in Cachexia Trial
Cancer patients losing dangerous amounts of weight have long had few medical options. A monoclonal antibody called ponsegromab might change that. Pfizer…
-
City of Hope Drug AOH1996 Moves Through Early Human Trial After Mouse Study Results
An investigational cancer medication called AOH1996 has entered Phase I clinical trials at City of Hope as of August 15, 2023, marking…
-
Moderna Ships Experimental Coronavirus Vaccine for Clinical Testing Quickly
U.S. biotechnology company Moderna Inc. dispatched its first shipment of an experimental coronavirus vaccine, designated mRNA-1273, to the National Institute of Allergy…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992